Abstract
SAR131675 is a potent and selective VEGFR-3 inhibitor. It inhibited VEGFR-3 tyrosine kinase (TK) activity and VEGFR-3 autophosphorylation in HEK cells with IC 50 s of 20nM and 45nM, respectively. SAR131675 dose-dependently inhibited the proliferation of primary human lymphatic cells, induced by the VEGFR-3 ligands VEGFC and VEGFD, with an IC 50 of about 20nM. SAR131675 was found to be highly selective for VEGFR-3 versus 107 receptors, enzymes, ion channels and 65 kinases. However, it exhibited a was moderately activitey on VEGFR-2 with a VEGFR-3/VEGFR-2 ratio of about 10. SAR131675 had no anti-proliferative activity on a panel of 30 tumors and primary cells, further demonstrating its high specificity and indicating that SAR131675 is not a cytotoxic or cytostatic agent. SAR131675 was very well tolerated in mice and demonstrated a potent antitumoral effect in several orthotopic and syngenic models including mammary 4T1 carcinoma and the RIP1.Tag2 tumors. Interestingly, it significantly reduced lymph nodes invasion and lung metastasis, demonstrating its antilymphangiogenic activity in vivo. Moreover, treatment of mice before resection of 4T1 primary tumors was sufficient to prevent metastasis. Tumor Associated Macrophages (TAMs) play an important role in tumor growth and metastasis. The expression of VEGFR-3 on TAMs has been recently described. F4/80 immunostaining clearly demonstrated showed that SAR131675 significantly reduced TAMs infiltration and aggregation in 4T1 tumors. Taken together, SAR131675 is the first highly specific VEGFR-3-TK inhibitor described to date, displaying significant anti-tumoral and antimetastatic activities in vivo through inhibition of lymphangiogenesis and TAMs invasion.
Introduction
In most solid tumors, the presence of metastases in regional lymph nodes is aoccur frequently event in the initial process of cancer dissemination and represents are a strong indicator of poor patient prognosis (1) . A number of clinical and experimental data suggests that migration of tumor cells into the lymph nodes is greatly facilitated by tumor lymphangiogenesis (2) .
One key molecule mediating tumor lymphangiogenesis is the vascular endothelial growth factor receptor-3 (VEGFR-3), a tyrosine kinase receptor recognized and activated by VEGFC and VEGFD, commonly expressed in malignant and tumor infiltrating stromal cells (3) . In experimental tumor models, VEGFC and VEGFD expression induces lymphangiogenesis and correlates with lymphatic invasion and nodal metastasis (4, 5) . In addition, agents neutralizing VEGFC and VEGFD, or blocking VEGFR-3 signaling, suppress development of new lymphatic vessels and tumor metastasis in experimental cancer models (6, 7) .
Although VEGFC and VEGFD are the sole ligands described so farto date as binding directly to VEGFR-3 (8, 9) , blunting of both ligands at the same time doesid not result in the embryonic blood vasculature defects seen in VEGFR-3 -/-mice (10-12). This suggests that additional ligands exist or that ligand-independent signaling occurs. Indeed, whereas VEGFA binds only to VEGFR-2, others and we and others have shown that VEGFA may induce formation of VEGFR-2/-3 heterodimers (13, 14) . This indicates suggests that in when cells expressing both receptors, VEGFR-3 inhibitors may also block some VEGFA signaling.
on Evidence has accumulated demonstratingThere is considerable evidence of the expression of VEGFR-3 in several primary tumors including colorectal, ovarian, gastric etc. (17) (18) (19) and. Iits upregulation in breast cancer has been shown to precede tumor cell invasion (20) . Interestingly, coexpression of VEGFR-3 with VEGFC in human cancer cells was associated with increased metastasis and poorer survival, suggesting a possible autocrine loop between VEGFC and VEGFR-3 in cancer cells (21, 22) .
Expression of VEGFR-3 has also been reported on macrophages after brain ischemia, kidney transplantation, chronic airway inflammation or corneal injury (23) (24) (25) (26) (27) and also on tumor associated macrophages (TAMs) (28, 29) . TAMs are critical regulators of angiogenesis and lymphangiogenesis; they express VEGFA and VEGFC and induce tipcell formation and fusion (16, (30) (31) (32) (33) . In addition they are thought to directly contribute to lymphatic vessel formation by trans-differentiating into lymphatic endothelial cells. (25, 28, (33) (34) Collectively, these data implicate VEGFR-3 in different processes of tumor growth and metastasis, suggesting that therapeutic intervention usingtargeting of VEGFR-3 as a target might selectively reduce tumor growth and metastasis 
Materials and methods
Reagents: Accustain®, Drabkin and the human recombinant hemoglobin were obtained from Sigma®. The Pproteome array Phospho-MAPK, the DuoSet ELISA Phospho-ERK1/2 and the recombinant proteins bFGF, VEGFA and VEGFD were purchased from R&D and VEGFC from ReliaTech, huVEGFR-1-TK from (Upstate), and huVEGFR-3-TK from Cell Signalling: huVEGFR-2-TK (was produced internally), huVEGFR-3-TK (Cell Signalling).
Animals: All animal treatment procedures described in this study were approved by the Animal Care and Use Committee of sanofi. Female BALB/cByj mice and RIP1.Tag2 mice on the C57Bl/6J background were obtained from Charles River France. authentication has beenwas performed. Cells were cultured in the culture medium in a humidified atmosphere of 5% CO2 and 95% air at 37°C. Cell viability was determined by trypan blue exclusion, and always exceeded 95%.
Complete cell culture medium for human cell proliferation was RPMI 1640 (Gibco Laboratories, Grand Island, NY) containing 10 % heat-inactivated FCS (Gibco Laboratories), 2 mM L-glutamine, 1mM sodium pyruvate, 100 UI/ml penicillin, 100 µg/ml streptomycin (Gibco Laboratories). Cells), were purchased from Cambrex, maintained in culture as described previously (35) and have beenwere tested and authenticated in the lab for the expression of VEGFR-3 and Prox1 as lymphatic cells markers. Cells were used up to passage 6. 4T1 mouse mammary adenocarcinoma cells were obtained from the ATTC (CRL-2539) and were maintained in RPMI 1640 containing 10% heat-inactivated FCS and 2mM L-glutamine.
Authentication of the cell line was done by expression of osteopontin as described below, and used up to passage 25. Experiments have beenwere performed as described previously (35) . Twenty four hours after transfection, the cells were treated during 1 hour with orthovanadate (100 mM), harvested, collected and, after counting, distributed in 5 ml tubes in the presence of the indicated concentration of SAR131675. After 30 min of incubation, the reaction was stopped by the addition of cold PBS supplemented by orthovanadate. Cells were then lysed with 150 µl of RIPA buffer over 15 min at 4°C, and then centrifuged for 10 min at 10,000xg. Supernatants were distributed in duplicate on 96-well plates precoated with the anti-Flag and left for 1 hour at room temperature. After 3 washes, the anti-phosphotyrosine conjugated to the HRP was added and incubated for 1 hour at room temperature. Seven days later, the animals were euthanatized and the sponges were removed, harvested and lysed in RIPA buffer at 4°C. After a centrifugation at 6,000xg, the supernatants were collected for further studiesanalysis. 
Statistical Analysis:
IC 50 values were obtained with using internal software Biost@t-SPEED v2.0 using with the 4-parameter logistic model. For the in vivo studies, results are given as mean ± sem.
Differences between groups were examined for statistical significance using two-analysis of variance (ANOVA) following Dunnett's test or confidence interval calculation as specified in the results part. Statistical analysis of data from the survival trial study was performed using a log-rank test. For tumor regression analysis in kinetic, two-way ANOVA with repeated measures was performed. 
Results
In vitro effect of SAR131675 on VEGFR-3 tyrosine kinase activity SAR131675 was identified afteris the result of high throughput screening and chemical optimization (Fig.1A) . Its ability to inhibit the kinase activity of VEGFR-3 was first determined by ELISA using recombinant human (rh)-VEGFR-3, with ATP and polyGT as substrates. SAR131675 dose-dependently inhibited rh-VEGFR-3-TK activity with an IC 50 of 23 ± 7nM (Fig.1B, n=4 ). Under the same conditions SU11248 (sunitinib) inhibited VEGFR-3-TK activity with an IC 50 of 10nM (a representative set of data with sunitinib is shown in supplementary Fig.1 ). SAR131675 is an ATP-competitive inhibitor; it inhibited VEGR-3-TK activity with a Ki of about 12nM, similar to its IC 50 value (supplementary Fig.1 ).
The effect of SAR131675 on VEGFR-3 auto-phosphorylation has beenwas evaluated after overexpression in HEK cells. SAR131675 was seen to be cell permeable and inhibited VEGFR-3 autophosphorylation in a dose-dependent manner with an IC 50 ranging from 30-50nM (Fig.1C) . In this assay, sunitinib inhibited VEGFR-3 autophosphorylation with an IC 50 ranging from 10-30nM (not shown). SAR131675 was also evaluated on two different variants of VEGFR-3 and also on murine flt4. The results indicated that SAR131675 inhibits has a similar inhibitory effect on both human variants and murine VEGFR-3 with similar activities (supplemental Fig.1 ).
The selectivity of SAR131675 towards VEGFR-1 and VEGFR-2 has beenwas evaluated using rh-VEGFR-1 and rh-VEGFR-2 ELISA assays as for VEGFR-3. SAR131675 In the same assay, sunitinib inhibited VEGFR-1 and VEGFR-2 with an IC 50 of 64nM and 14nM, respectively (not shown). In the autophosphorylation assay in HEK cells, SAR131675 inhibited VEGFR-1 autophosphorylation with an IC 50 of about 1µM and VEGFR-2 with an IC 50 of about 280nM (Table 1 ). In the same assay, sunitinib inhibited VEGFR-1 and VEGFR-2 with an IC 50 of 64nM and 14nM, respectively (not shown).
Thus, tThese results confirm that SAR131675 moderately inhibits VEGFR-2 and shows has very low activity towardslittle effect on VEGFR-1, demonstrating a good selectivity toward for VEGFR-3, in contrast towhich is not the case for sunitinib.
In order to further confirm the activity of SAR131675 on VEGFR-2, we used Porcine Aortic Endothelial Cells (PAEC) stably expressing human VEGFR-2. SAR131675 inhibited VEGFA-induced VEGFR-2 phosphorylation in a dose dependent manner, with an IC 50 of 239nM, confirming the results obtained in HEK293T cells after VEGFR-2 overexpression (Fig.1D, E) .
The selectivity of SAR131675 was further confirmed as it was inactive on a panel of 65 kinases, on a panel of 107 non-kinase enzymes and receptors and on 21 ion channels (supplementary tables 1, 2A and 2B, respectively). We further evaluated the selectivity ofruled out the eventuality of any non-specific cytotoxic or cytostatic effect of SAR131675 by investigating its effect on the proliferation of tumor cell lines. confirming its moderate activity toward on VEGFR-2 and had no effect on FGF2-induced proliferation. In the same experiment, sunitinib inhibited VEGFA, -C and -D induced survival with an IC 50 of about 5nM and, consistent with reported data (38) , it had no effect on FGF2-induced survival (supplementary Fig.1 ).
We then evaluated the effect of SAR131675 on HLMVEC migration induced by VEGFA or VEGFC in Boyden's chambers. SAR131675 potently inhibited VEGFC-induced migration with an IC 50 <30nM (Fig.2B) and VEGFA-induced migration with an IC 50 of about 100nM (Fig.2C) .
Using the PhosphoMAP array in HLMVEC, Erk has beenwas identified as the major phosphorylated kinase upon VEGFC-stimulation (Fig.2D) . SAR131675, significantly and dose dependently inhibitsed VEGFC-induced Erk phosphorylation, with an IC 50 of about 30nM (Fig.2E) , demonstrating confirming that SAR131675 is a potent inhibitor of VEGFR-3 signaling. 
In vivo Eeffect of SAR131675 on angiogenesis and lymphangiogenesis in non tumoral models In vivo
The in vivo activity of SAR131675 was first determined investigated oin embryonic angiogenesis using the zebrafish model (Danio rerio) expressing GFP under the control of a vascular specific promoter. Treatment with SAR131675 started when the blood flow begains, 24 hours post fertilization. Embryos treated with 3µM SAR131675 for 24h, showed lees importantfewer intersegmental vessels in the tail compared to control embryos and at the dose of 10µM intersegmental vessels largely failed to form at the dose of 10µM (Fig.3A) . Thus, in this model, SAR131675 efficiently impaired zebrafish embryonic vasculogenesis. Using a corneal model, a high concentration of FGF2 concentration has been reported to induce VEGFR-3-dependent lymphangiogenesis (39) . We therefore developed a similar approach by subcutaneous implantation of a sterile sponge disc impregnated with FGF2 in mice (Fig.3B ). In this model, FGF2 induces angiogenesis, as assessedthat is measured by CD31 immunostaining and hemoglobin content (Fig.3D) , as well as lymphangiogenesis as evidencedthat is measured by LYVE-1 immunostaining and by VEGFR-3 quantification by using ELISA (Fig.3E ). FGF2 induced a 3-to 5-fold induction increase of hemoglobin and VEGFR-3, thus confirming that in these conditions, FGF2 induces angiogenesis and lymphangiogenesis (Fig.3I) .
Treatment of mice with SAR131675 (30, 100 or 300 mg/kg/day) was started on the day of the sponge implantation. Seven days later, SAR1316765 at 100 mg/kg/day had significantly reduced the levels of VEGFR-3 ( Fig.3H ) and hemoglobin content (Fig.3I) by about 50%, (p<0.001). TreatmentAt with 300 mg/kg/day the gave levels of VEGFR-3 
and hemoglobin that were similar to those of the control group. In consequenceThus, SAR131675 efficiently abrogates lymphangiogenesis and angiogenesis induced in vivo by FGF2.
Furthermore, at 100mg/kg SAR131675 did not show any effect on arterial pressure whereas at 300mg/kg, a minor and transient increase of blood pressure has beenwas observed (supplementary Fig.2) . While,Since the inhibition of VEGFR-2 signaling is known to increase blood pressure, and consistently withgiven our in vitro results, we concluded that SAR131675 at a dose of 300mg/kg is able to inhibit both VEGFR-2 and VEGFR-3 signaling in vivo. In consequence 100mg/kg was the highest dosage will be used in all furthersubsequent in vivo studies.
Effect of SAR131675 on carcinogenesis in the RIP1.Tag2 mice model
The RIP1.Tag2 transgenic mouse is a well-characterized multistep carcinogenesis model, which arises from targeted oncogene expression in the insulin-producing beta cells (40) .
We investigated the efficacy of SAR131675 on the angiogenic switch (prevention trialstudy), on asymptomatic small tumors (intervention trialstudy) and finally on advanced near-end-stage cancers (survival study) as illustrated in Fig.4A .
In the prevention trialstudy, 5 weeks treatment with SAR131675 was well tolerated and the number of angiogenic islets in the pancreas from theof SAR131675 treated mice was significantly decreased (42%, p<0.001) compared to the vehicle treated group (Fig.4B) .
In an the intervention trialstudy, daily oral administration of SAR131675 from Week 10 to Week 12.5, caused a significant decrease of thein tumor burden (62%, p<0.05, Fig.4C ).
In these two protocols studies a significant decrease of the CD31 positive vessels was significantly extended the median survival age of the mice to 15 weeks (Fig.4D, p<0.01 ).
Taken together, these results demonstrate that SAR131675 is able to prevent the angiogenic switch and slow the tumor growth.
Effect of SAR131675 on growth and metastases of 4T1 mammary carcinoma tumors in mice
4T1 cells were implanted orthotopically into mammary fat pads in mice and who were then orally treated with vehicle or with SAR131675 (at 30 and 100mg/kg/day) from day 5 to day 21 after tumor implantation. Fig.3E and F) . Interestingly, the osteopontin content dramatically increased in sentinel lymph nodes, indicating an infiltration by metastatic 4T1 cells (Fig.5C) . SAR131675, at 100mg/kg significantly reduced the osteopontin content in lymph nodes (56%, p<0.01), demonstrating a potent effect ofindicating that SAR131675 has a potent effect on lymph node invasion by 4T1 cells (Fig. 5C ).
At day 21, the number of macroscopic lung metastases number was reduced in the treated groups by 17% (ns) and 28% (p<0.05) at 30 and 100 mg/kg/d, respectively (Fig.5D ).
Although it sunitinib strongly reduced tumor growth (82%, supplementary Fig.4A ), it is interesting to note that in this model, sunitinib sunitinib at 50mg/kg/d had no effect on the number of lung metastaseis number (supplementary Fig.4A ).
Altogether these results demonstrate that SAR131675 is a potent antitumoral agent, acting through anti-angiogenic and anti-lymphangiogenic effects. Moreover it reduces the migration of cancer cells into lymph nodes and lungs.
Effect of preoperative treatment with SAR131675 on distant metastasis
Recent reports suggest that anti-angiogenic compounds may promote tumor invasion after resection of the primary tumor (41) . We evaluated the effect of SAR131675 on distant metastasis in the 4T1 model after resection of the primary tumor (Fig.6A) . (Fig.6B and C) . SAR131675 induced an important decrease in the number of lung metastaseis (Fig.6D) , whether the treatment was pursued after primary tumor resection or not. This indicates that SAR131675 blocks early events of tumor escape and metastasis and suggests that treatment prior to tumor resection could be sufficient to prevent tumor metastasis. As before, sunitinib was also more efficient on in reducing tumor growth, but showed no significant effect on the number of lung metastaseis, number whatever the treatment schedule (supplementary Fig.4B ).
Effect of SAR131675 on macrophage infiltration
TAMs play an important role in tumor promotion and metastasis (42) . We analyzed macrophage infiltration (with F4/80 immunoustaining), using sections from 4T1 mammary tumors and from the RIP1.Tag2 pancreas.
In 4T1 tumors, macrophages were mainly located at the periphery of the tumor at day 12-post implantation, whereas they infiltrated the tumor and formed clusters in more advanced tumors (day 21, Fig.7A ). Treatment with SAR131675 decreased macrophage infiltration and clustering as illustrated in figure 7A . and Cconsistently, SAR131675 reduced F4/80 levels in tumors as measured by an ELISA assay (Fig.7B) .
A strong decrease of F4/80 staining in the RIP1.Tag2 model was also observed in the angiogenic islets and the tumors from SAR131675-treated mice (sSupplementary Fig.3G ).
These results indicate that reduction of tumor growth induced by SAR131675 in the Although angiogenesis inhibitors demonstrate antitumor effects in several mouse models, they have been reported to concomitantly elicit increase of lymphatic and distant metastasis. Indeed, an anti-VEGFR-2 neutralizing antibody reduces tumor vasculature and volume and it also increases incidence of lymph node and liver metastasis in RIP1.Tag2 mice (47, 48) . In thise same model, SAR131675 reduced tumor volume in both prevention and intervention studies without any prominent invasive fronts in the treated animals. Increased metastasis was also observed in mice receiving short-term therapy with sunitinib (41) . In the 4T1 model, SAR131675, but not sunitinib, significantly reduced lymph node invasion and distant metastasis. In addition, short-term treatment prior to tumor resection with SAR131675, but not with sunitinib, prior to tumor 
